A first-in-class bispecific antibody targeting kallikreins 5 and 7 and interleukin 13, in Phase 1 clinical trials for atopic dermatitis.
TRIV-573 is a half-life extended, second-generation bispecific antibody that combines KLK5/7 inhibition with a highly potent anti-IL-13 arm. The molecule is designed to repair the skin barrier while further reducing Th2 inflammation, addressing the root cause of atopic dermatitis rather than merely modulating inflammatory pathways.
Triveni Bio is advancing TRIV-573 into a Phase 2 efficacy trial in atopic dermatitis following positive Phase 1 data. The company is also examining kallikrein 5/7 biology in other barrier-related conditions, expanding the potential therapeutic applications of this dual-target approach.
| Attribute | Triv-573 | Dupixent | Ebglyss | |
|---|---|---|---|---|
| Provider |  |  |  | |
| Founded | 2023 | 1973 | 1876 | |
| Sells To | B2B, Enterprise | Enterprise | Consumers, Enterprise | |
| Pricing Model | Licensing, Pre-Revenue | Recurring | Recurring, Software, Transactional | |
| Ownership | Private, Venture-backed | Public | Public |
Provider
Founded 2023
Sells To B2B, Enterprise
Pricing Model Licensing, Pre-Revenue
Ownership Private, Venture-backed
Provider
Founded 1973
Sells To Enterprise
Pricing Model Recurring
Ownership Public
Provider
Founded 1876
Sells To Consumers, Enterprise
Pricing Model Recurring, Software, Transactional
Ownership Public
First-in-class once-daily oral small-molecule candidate with a novel non-kinase mechanism in Phase 2a for atopic dermatitis and asthma.
Prescription dermatology medicines for moderate-to-severe skin conditions.
First-in-class once-daily oral small-molecule candidate with a novel non-kinase mechanism in Phase 2a for atopic dermatitis and asthma.
Prescription dermatology medicines for moderate-to-severe skin conditions.
